Jointown Pharmaceutical Group Co Ltd (600998) - Net Assets
Based on the latest financial reports, Jointown Pharmaceutical Group Co Ltd (600998) has net assets worth CN¥35.07 Billion CNY (≈ $5.13 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥112.28 Billion ≈ $16.43 Billion USD) and total liabilities (CN¥77.21 Billion ≈ $11.30 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 600998 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥35.07 Billion |
| % of Total Assets | 31.23% |
| Annual Growth Rate | 21.18% |
| 5-Year Change | 31.14% |
| 10-Year Change | 241.2% |
| Growth Volatility | 32.71 |
Jointown Pharmaceutical Group Co Ltd - Net Assets Trend (2007–2024)
This chart illustrates how Jointown Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Jointown Pharmaceutical Group Co Ltd asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Jointown Pharmaceutical Group Co Ltd (2007–2024)
The table below shows the annual net assets of Jointown Pharmaceutical Group Co Ltd from 2007 to 2024. For live valuation and market cap data, see 600998 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥33.59 Billion ≈ $4.92 Billion |
+13.96% |
| 2023-12-31 | CN¥29.48 Billion ≈ $4.31 Billion |
+2.76% |
| 2022-12-31 | CN¥28.69 Billion ≈ $4.20 Billion |
+5.96% |
| 2021-12-31 | CN¥27.07 Billion ≈ $3.96 Billion |
+5.68% |
| 2020-12-31 | CN¥25.62 Billion ≈ $3.75 Billion |
+16.61% |
| 2019-12-31 | CN¥21.97 Billion ≈ $3.21 Billion |
+7.78% |
| 2018-12-31 | CN¥20.38 Billion ≈ $2.98 Billion |
+4.32% |
| 2017-12-31 | CN¥19.54 Billion ≈ $2.86 Billion |
+62.67% |
| 2016-12-31 | CN¥12.01 Billion ≈ $1.76 Billion |
+21.99% |
| 2015-12-31 | CN¥9.85 Billion ≈ $1.44 Billion |
+21.74% |
| 2014-12-31 | CN¥8.09 Billion ≈ $1.18 Billion |
+51.47% |
| 2013-12-31 | CN¥5.34 Billion ≈ $781.30 Million |
+10.41% |
| 2012-12-31 | CN¥4.84 Billion ≈ $707.64 Million |
+12.37% |
| 2011-12-31 | CN¥4.30 Billion ≈ $629.75 Million |
+7.62% |
| 2010-12-31 | CN¥4.00 Billion ≈ $585.15 Million |
+139.06% |
| 2009-12-31 | CN¥1.67 Billion ≈ $244.77 Million |
+13.24% |
| 2008-12-31 | CN¥1.48 Billion ≈ $216.16 Million |
+15.34% |
| 2007-12-31 | CN¥1.28 Billion ≈ $187.41 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jointown Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3008.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥14.07 Billion | 51.65% |
| Common Stock | CN¥5.04 Billion | 18.51% |
| Other Components | CN¥8.13 Billion | 29.84% |
| Total Equity | CN¥27.24 Billion | 100.00% |
Jointown Pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of Jointown Pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China Galaxy Securities Co Ltd
F:CGL
|
$3.82 Billion |
|
Grandblue Environment Co Ltd
SHG:600323
|
$3.82 Billion |
|
Carnival Corporation & plc
F:POH1
|
$3.82 Billion |
|
Chipbond Technology
TWO:6147
|
$3.82 Billion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
$3.81 Billion |
|
Peyto Exploration&Development Corp
TO:PEY
|
$3.81 Billion |
|
Kenon Holdings
TA:KEN
|
$3.81 Billion |
|
Amneal Pharmaceuticals, Inc. Class A Common Stock
NASDAQ:AMRX
|
$3.81 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jointown Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 23,983,172,247 to 27,243,192,000, a change of 3,260,019,753 (13.6%).
- Net income of 2,507,391,953 contributed positively to equity growth.
- Dividend payments of 1,553,504,594 reduced retained earnings.
- Share repurchases of 268,150,093 reduced equity.
- Other factors increased equity by 2,574,282,487.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥2.51 Billion | +9.2% |
| Dividends Paid | CN¥1.55 Billion | -5.7% |
| Share Repurchases | CN¥268.15 Million | -0.98% |
| Other Changes | CN¥2.57 Billion | +9.45% |
| Total Change | CN¥- | 13.59% |
Book Value vs Market Value Analysis
This analysis compares Jointown Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.95x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.88x to 0.95x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥1.79 | CN¥5.17 | x |
| 2008-12-31 | CN¥0.81 | CN¥5.17 | x |
| 2009-12-31 | CN¥0.92 | CN¥5.17 | x |
| 2010-12-31 | CN¥1.95 | CN¥5.17 | x |
| 2011-12-31 | CN¥1.92 | CN¥5.17 | x |
| 2012-12-31 | CN¥1.54 | CN¥5.17 | x |
| 2013-12-31 | CN¥1.35 | CN¥5.17 | x |
| 2014-12-31 | CN¥1.86 | CN¥5.17 | x |
| 2015-12-31 | CN¥2.15 | CN¥5.17 | x |
| 2016-12-31 | CN¥2.58 | CN¥5.17 | x |
| 2017-12-31 | CN¥4.00 | CN¥5.17 | x |
| 2018-12-31 | CN¥3.69 | CN¥5.17 | x |
| 2019-12-31 | CN¥3.39 | CN¥5.17 | x |
| 2020-12-31 | CN¥4.09 | CN¥5.17 | x |
| 2021-12-31 | CN¥4.51 | CN¥5.17 | x |
| 2022-12-31 | CN¥4.67 | CN¥5.17 | x |
| 2023-12-31 | CN¥4.74 | CN¥5.17 | x |
| 2024-12-31 | CN¥5.43 | CN¥5.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jointown Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.20%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.65%
- • Asset Turnover: 1.48x
- • Equity Multiplier: 3.76x
- Recent ROE (9.20%) is below the historical average (9.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 12.73% | 1.22% | 2.95x | 3.52x | CN¥34.24 Million |
| 2008 | 14.06% | 1.24% | 2.85x | 3.97x | CN¥58.51 Million |
| 2009 | 18.26% | 1.57% | 2.64x | 4.39x | CN¥134.77 Million |
| 2010 | 9.27% | 1.69% | 2.62x | 2.09x | CN¥-28.24 Million |
| 2011 | 9.10% | 1.51% | 2.10x | 2.88x | CN¥-36.93 Million |
| 2012 | 9.00% | 1.40% | 1.99x | 3.23x | CN¥-45.94 Million |
| 2013 | 9.37% | 1.43% | 1.80x | 3.65x | CN¥-32.02 Million |
| 2014 | 7.19% | 1.37% | 1.70x | 3.09x | CN¥-219.35 Million |
| 2015 | 7.42% | 1.40% | 1.52x | 3.48x | CN¥-240.97 Million |
| 2016 | 7.77% | 1.42% | 1.59x | 3.43x | CN¥-251.06 Million |
| 2017 | 7.90% | 1.95% | 1.42x | 2.84x | CN¥-384.53 Million |
| 2018 | 7.26% | 1.54% | 1.31x | 3.61x | CN¥-506.13 Million |
| 2019 | 9.21% | 1.74% | 1.40x | 3.79x | CN¥-148.87 Million |
| 2020 | 14.09% | 2.77% | 1.37x | 3.70x | CN¥892.39 Million |
| 2021 | 10.46% | 2.00% | 1.42x | 3.67x | CN¥107.47 Million |
| 2022 | 8.46% | 1.48% | 1.52x | 3.74x | CN¥-379.02 Million |
| 2023 | 9.06% | 1.45% | 1.62x | 3.87x | CN¥-224.27 Million |
| 2024 | 9.20% | 1.65% | 1.48x | 3.76x | CN¥-216.93 Million |
Industry Comparison
This section compares Jointown Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $8,434,717,101
- Average return on equity (ROE) among peers: 10.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jointown Pharmaceutical Group Co Ltd (600998) | CN¥35.07 Billion | 12.73% | 2.20x | $3.81 Billion |
| China National Accord Medicines Corp Ltd (000028) | $8.91 Billion | 13.31% | 1.39x | $1.74 Billion |
| Shenzhen Glory Medical Co Ltd (002551) | $2.82 Billion | 2.12% | 0.68x | $442.93 Million |
| Shandong Realcan Pharmaceutical Co Ltd (002589) | $5.64 Billion | 0.36% | 1.96x | $700.19 Million |
| China National Accord Medicines Corp Ltd (200028) | $357.13 Million | 11.35% | 0.25x | $126.15 Million |
| Qingdao Baheal Medical INC. (301015) | $2.60 Billion | 26.55% | 1.73x | $1.90 Billion |
| China Meheco Co Ltd (600056) | $1.54 Billion | 15.23% | 0.77x | $2.27 Billion |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) | $33.64 Billion | 11.79% | 1.22x | $4.66 Billion |
| China National Medicines Corp Ltd (600511) | $399.62 Million | 6.55% | 1.02x | $3.16 Billion |
| Liaoning Cheng Da Co Ltd (600739) | $20.00 Billion | 4.74% | 0.66x | $2.66 Billion |
About Jointown Pharmaceutical Group Co Ltd
Jointown Pharmaceutical Group Co., Ltd engages in pharmaceutical distribution and supply chain business in China and internationally. It is also involved in general agency brand promotion; pharmaceutical industrial self-production and OEM; and pharmaceutical new retail and ten-thousand store alliance plan businesses. In addition, the company provides medical health and technology value-added serv… Read more